<DOC>
	<DOCNO>NCT00944593</DOCNO>
	<brief_summary>Diabetic 'Gastroparesis ' 'Gastroenteropathy ' condition patient suffer episode nausea , vomit , abdominal bloating pain eating . These symptom occur absence structural abnormality stomach , rather abnormal gastric function underlies condition . Up one five patient type I diabetes experience symptom consistent diagnosis . The effect diabetic control , physical health emotional quality life severe . Patients respond reliably general supportive management conventional medication . Surgical option disappointing result . The need effective treatment acknowledge universally . Feeding small bowel beyond stomach ( jejunal feeding ) establish management diabetic patient gastroenteropathy malnourish due poor oral intake . The benefit assume secondary improve nutrition diabetic control ; however assertion never study . Recently observe patient severe gastroenteropathy recover promptly could eat normally hour jejunal feeding . These observation suggest jejunal feed 'quasi-pharmacological ' effect patient gastroenteropathy . One attractive explanation observation gastroenteropathy represent failure oral intake 'switch ' stomach fast fed state . According hypothesis , jejunal feeding 'restores ' normal fed state bypass dysfunctional stomach . This project ass effect feed gastrointestinal ( GI ) sensory motor function diabetic gastroenteropathy . Healthy volunteer diabetic control without symptom also investigate . Studies ass : 1 . Effects GI symptom function gastric distension fast fed state 2 . Effects GI symptom function oral vs. nasogastric delivery test meal 3 . A trial gastric feeding without prior jejunal feeding GI symptom function Non-invasive magnetic resonance imaging ( MRI ) technique apply assess complex gastric response feeding . In addition effect feed symptom gastric function relate alteration GI hormone autonomic nervous activity ( eg cardiovagal tone ) ass integrate response GI tract feed fails patient diabetic gastroenteropathy . The primary aim project ass effectiveness jejunal feeding management diabetic gastroenteropathy . However , define process 'switch ' gastric function fast fed state control gastric emptying , hope also identify candidate target effective pharmacologic treatment severe disease . - Trial medical device</brief_summary>
	<brief_title>Gastric vs Jejunal Feeding Diabetic Gastroparesis</brief_title>
	<detailed_description />
	<mesh_term>Gastroparesis</mesh_term>
	<criteria>Inclusion criterion : â€¢ Type 1 diabetes mellitus , confirm history persistent insulin treatment 12 month ' less diagnosis , fast C peptide concentration &lt; 0.16nmol/L.74 At least moderate symptom gastroenteropathy ( GCSI &gt; 27 ) Delayed gastric empty breath test perform screening ( result available ) Disease control Type 1 diabetes mellitus , confirm history persistent insulin treatment 12 month ' less diagnosis , fast C peptide concentration &lt; 0.16nmol/L.74 Not mild symptom gastroenteropathy / dyspepsia ( GCSI &lt; 14 ) . Normal gastric empty breath test perform screening ( result available ) Normal control Healthy volunteer recruit advertisement . Not mild symptom gastroenteropathy / dyspepsia ( GCSI &lt; 14 ) . Normal gastric empty breath test perform screening ( result available ) General inclusion criterion Aged least 18 55 year . Body Mass Index : 1927 kg/m2 Ability communicate investigator comply requirement entire study . Ability provide write , informed consent Exclusion criterion : General exclusion criterion Gross retention gastric content ( e.g . bezoar ) evidence peptic ulcer disease significant pathology ( reflux oesophagitis ) upper gastrointestinal endoscopy History gastrointestinal surgery ( except appendicectomy hernia repair ) . History abdominal radiotherapy malignancy Mental impairment psychological disease limit ability comply study requirement Progressive unstable comorbid condition require treatment preclude safe endoscopic placement nasojejunal feeding tube . Patients risk pregnancy without effective contraception Evidence history drug alcohol abuse within two year . Unable unwilling stop medication influence upper GI motility</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2012</verification_date>
</DOC>